Samtleben W, Randerson D H, Blumenstein M, Habersetzer R, Schmidt B, Gurland H J
J Clin Apher. 1984;2(2):163-9. doi: 10.1002/jca.2920020204.
Membrane plasmapheresis was introduced in 1978 as a new method for performing therapeutic plasma exchange. Its principal advantages over traditional techniques include speed, ease of performance, and ready adaptability to clinical centers already performing routine extracorporeal therapy. The appearance of a membrane plasmapheresis circuit (vascular access, anticoagulation, connectology) is similar to that of hemodialysis and especially hemofiltration; the operating protocols (treatment time, filtration rates, pressures, pharmacokinetics) are quite different. Particular attention must be paid to avoiding operating conditions that lead to hemolysis. In clinical use membrane plasma separation is as effective as centrifugal plasma exchange in removing plasma proteins. The sieving coefficients for proteins with a molecular weight (MW) ranging from 67,000 (albumin) to 2,400,000 (beta-lipoprotein) daltons are unity. An exchange of one patient plasma volume has been shown to cause a 55% reduction of the serum levels of intravascular proteins. There are no significant differences between membrane and centrifugal plasmapheresis in substitution fluid requirements (human albumin or fresh frozen plasma), indications for treatment and complications. The next major advance in plasmapheresis technology will almost certainly be development of a "closed loop" circuit in which filtered plasma is treated to remove the offending moiety and returned to the patient. This would eliminate both the cost and the possible side effects of replacement fluid. Membrane-based systems are already available for removing cryoglobulins or proteins with MW of at least 900,000 daltons.
膜式血浆置换术于1978年被引入,作为一种进行治疗性血浆置换的新方法。与传统技术相比,其主要优点包括速度快、操作简便,并且易于适应已经开展常规体外治疗的临床中心。膜式血浆置换回路(血管通路、抗凝、连接技术)的外观与血液透析尤其是血液滤过相似;但操作方案(治疗时间、滤过率、压力、药代动力学)却大不相同。必须特别注意避免导致溶血的操作条件。在临床应用中,膜式血浆分离在去除血浆蛋白方面与离心式血浆置换同样有效。分子量(MW)范围从67,000(白蛋白)到2,400,000(β-脂蛋白)道尔顿的蛋白质的筛系数均为1。已证明置换一个患者血浆量可使血管内蛋白质的血清水平降低达55%。在置换液需求(人白蛋白或新鲜冷冻血浆)、治疗适应证和并发症方面,膜式血浆置换与离心式血浆置换之间没有显著差异。血浆置换技术的下一个重大进展几乎肯定是开发一种“闭环”回路,在该回路中对滤过的血浆进行处理以去除有害成分,然后再回输给患者。这将消除置换液的成本和可能的副作用。基于膜的系统已经可用于去除冷球蛋白或分子量至少为900,000道尔顿的蛋白质。